Salarius Pharmaceuticals Inc. has announced that it entered into a definitive merger agreement for a business combination with Decoy Therapeutics, Inc., a privately held preclinical biopharmaceutical company. Under the agreement, Decoy will merge with a wholly owned subsidiary of Salarius. Upon completion of the merger, the newly formed company will be named Decoy Therapeutics. The transaction is subject to closing conditions set forth in the agreement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Salarius Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001615219-25-000125), on September 09, 2025, and is solely responsible for the information contained therein.